intermediates industry, the scale of opportunities and challenges faced
1. Development trend of pharmaceutical intermediates industry
(1) The medical industry continues to shift to Asia
(2) The added value and process complexity of products are constantly improved
(3) The requirements for energy conservation and environmental protection are becoming increasingly strict
(4) The degree of automation continues to improve
2. Characteristics of pharmaceutical intermediates industry
Pharmaceutical intermediates are fine chemical products in the process of chemical raw materials to bulk drugs or pharmaceutical production, which are usually specialized chemicals with high technology intensity and high added value. Because of the variety of medicine, chemical structure is complex, so the demand for intermediate variety is more. Different from the large-scale chemical production process, the production process of pharmaceutical intermediates usually has the characteristics of miniaturization, batch batch and multi-function. Combined with the experience of large-scale chemical production, some pharmaceutical intermediates production enterprises have developed relatively large-scale, automatic, continuous and modular production processes. The upstream industry of pharmaceutical intermediates is basic chemical raw materials, and the downstream industry is chemical bulk drugs and chemical pharmaceutical preparations.
3.Opportunities for the pharmaceutical intermediates industry
(1) The scale of industry demand continues to expand, and the product application field continues to extend
(2) National industrial policy support, industry standardization, orderly development
(3) Development opportunities brought by the transfer of global pharmaceutical intermediates industry
(4) The introduction of policies related to "purchasing with volume" in the medical reform
4. Challenges facing the industry
(1) The influence of national policies on the use of antibiotics
(2) Stricter requirements for energy conservation and environmental protection
(3)The financial strength of some enterprises in the pharmaceutical intermediates industry is weak.
Post time: Nov-01-2022